Bavarian Nordic A S

to this Q3 update from the Nordic. Yes, my name is Rolf Sørensen, DPI Investor Relations, on quite a dramatic day for the company. Today, here as usual, we have our president and CEO, Paul Chapman, and our CFO, Henry Guell, to provide comments and presentation. on our Q3 and nine-month period presentation. And after that, it will be followed by Q&A, as usual. Before we start, I just want quickly to go through the forward-looking statements. Forward-looking statements involve risks, uncertainties, and other factors, many of which are outside our control, but could cause actual results to differ materially from the results discussed. forward-looking statements include statements concerning our plans, objectives, goals, future events, performance, and other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. With these points, I will hand it over to you, Paul, for the presentation.

Thanks, Rolf, and welcome, everyone, to our quarterly update. If you turn to slide three, I'll just run through the key highlights. And we're having an extremely successful year. And the Q3 was as planned, if not better than planned, in terms of the numbers. We've seen our travel health portfolio grow more than anticipated. If you turn to slide three, I'll just run through the key highlights. Sorry about that. Where was I? Yeah. So our travel health portfolio has grown significantly compared to this time last year. And in fact, we beat the consensus in terms of our revenues for travel health. In public preparedness, we're dealing with yet another public health crisis in MPOCs. And we've recorded very strong sales in line with our plans. And we stick to our overall guidance by year end. We're gearing up also for our launch of our new vaccine for chikungunya, and that vaccine is currently being reviewed by the regulators in both the US and in Europe with a planned approval for next year and a launch. To prepare for that launch, we're expanding our commercial presence, which I'll go into in more of the slides. That's both to take over some of the markets that we had originally given to Valneva, but also to prepare for Chikungunya. The good news is that as we have stepped up, once again, in terms of our mpox vaccine, in terms of supplying both to Europe and also for Africa, we have secured very strong orders for next year and have already 2.4 billion kroner in revenues for our public preparedness business for next year. So a great first nine months and plan to end according to the guidance at year end. We go to slide four. As I said, our travel health business has really gone from strength to strength. Yet again, very strong growth compared to this time last year. On rabies, we've seen strong growth in both the US and in Germany. We have completed the tech transfer for our rabies from GSK. And I want to say just a couple of words on that, as this was a four-year program, which many people either thought was very long or within the industry thought was going to be very, very difficult to achieve. Rabies is an incredibly difficult vaccine to produce and to test and release. And I'm extremely proud to say that we have completed the tech transfer and all the regulatory approvals are in for this difficult vaccine. And we've achieved this on time and on budget. And this will lead to an improvement in the gross margin, an impact of which we will see the full impact by 27. On TBE, we've also seen strong sales in Germany. And here the tech transfer is progressing according to plan and will be completed next year. In terms of cholera and typhoid, these are two assets that we're relaunching. That relaunch is still moving forward, and we still believe we can return these two assets to an overall combined revenue of $100 million in the coming years. So really a very strong performance on our travel health portfolio.

We go to the next slide.